Rexahn Pharmaceuticals Inc., a pharmaceutical company focused on commercializing leading oncology therapeutics, CNS disorders and sexual dysfunction, recently formed a Parkinson’s Disease Scientific Advisory Board (SAB) comprised of leading medical researchers in neurology. The SAB will work with Rexahn for the clinical development strategy for the company’s CNS drug candidate Serdaxin.

SAB Chairman Dr. William Weiner is the director of the Maryland Parkinson’s Disease and Movement Disorders Center, and professor and chair of the Department of Neurology at the University of Maryland School of Medicine. With more than 40 years of Parkinson’s disease related research behind him, Dr. Weiner recognizes the potential of Serdaxin.

“With Serdaxin, Rexahn is developing a promising therapeutic for Parkinson’s disease, a condition in great need of effective treatment options. I am excited to help contribute to the design of Serdaxin’s clinical trials and ultimately to help guide this promising drug into the clinic, where it may one day help treat patients suffering from this debilitating illness,” Dr. Weiner stated in the press release.

Other leading neurology researchers joining Dr. Weiner on SAB are: Kenneth Marek, MD, president and senior scientist at Institute for Neurodegenerative Disorders, New Haven, Conn.; Andrew Feigin, MD, professor for the Departments of Molecular Medicine and Neurology At Hofstra University School of Medicine; and Fernando Pagan, MD, associate professor of neurology, co-director of Movement Disorders Program, medical director of National Parkinson Foundation Center of Excellence at Georgetown University Hospital.